We enclose herewith the report dated May 13, 2026, issued by the Monitoring Agency i.e., CARE Rating Agency for the quarter ended March 31, 2026. For more details, please refer attachment.
EMBDL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
CARE Ratings has submitted its Q4 FY26 monitoring report for Embassy Developments' ₹3,908.14 crore preferential issue (comprising equity shares and convertible warrants at ₹111.51 per share). The company received ₹3,510.66 crore in total proceeds as 4.75 crore warrants lapsed due to non-exercise within the prescribed period, resulting in forfeiture of ₹132.49 crore upfront amount and non-receipt of ₹397.48 crore balance consideration. All funds have been fully deployed toward stated objects including Embassy Residency acquisition (₹119.56 crore), Embassy Eden (₹465.70 crore), Blu Annex FSI rights (₹1,233.25 crore), Sky Forest Projects discharge (₹86.71 crore), growth initiatives (₹680.24 crore), and general corporate purposes (₹807.92 crore). No deviations from offer document objects were observed. Of the 25.91 crore warrants issued, 21.16 crore were converted into equity shares between April 2024 and December 2025.
Positive for shareholders as the entire ₹3,510.66 crore raised has been utilized for acquisitions and corporate purposes with no material deviations reported. The warrant conversions have strengthened the company's equity base. The lapse of nearly 4.75 crore warrants with forfeited upfront payments indicates commitment from participating investors.